The Ross procedure is an open-heart surgery that replaces a diseased aortic valve with the patient’s own pulmonary valve. Because the replacement tissue is living and comes from your own body, it functions almost identically to a healthy native aortic valve, with excellent blood flow characteristics and no need for lifelong blood thinners. A donor valve from preserved human tissue is then placed where the pulmonary valve was removed.
How the Surgery Works
Your heart has four valves. The aortic valve controls blood flow from the heart into the aorta, your body’s largest artery. The pulmonary valve controls flow from the heart to the lungs. These two valves are similar in structure, which makes the swap possible.
During the Ross procedure, the surgeon opens the chest through the breastbone and places the patient on a heart-lung bypass machine. The diseased aortic valve is removed, and the pulmonary valve is carefully excised along with a portion of the surrounding tissue. The coronary arteries, which supply blood to the heart muscle itself, are detached from the old aortic root and reattached to the transplanted pulmonary valve in its new position. This is one of the most technically demanding parts of the operation.
Once the pulmonary valve is secured in the aortic position, a preserved donor pulmonary valve (called a homograft) is sewn into the spot where the original pulmonary valve was removed. The right side of the heart, which pumps blood only to the lungs at much lower pressure, tolerates a donor valve well. Before closing, the surgical team uses an ultrasound probe to confirm both valves are functioning properly.
Who Is a Good Candidate
The Ross procedure is most commonly performed for aortic stenosis (a narrowed valve that forces the heart to work harder) or aortic regurgitation (a leaky valve that lets blood flow backward into the heart). Both conditions can eventually lead to heart failure if untreated. Candidates are typically younger adults, often under 60, because the primary advantage of the Ross procedure is long-term durability without blood thinners. For patients in this age range, the operation can restore a normal life expectancy.
Children and adolescents are particularly strong candidates. Unlike mechanical or tissue valves, which come in fixed sizes, the transplanted pulmonary valve is living tissue that grows along with the patient. Most children who receive a standard prosthetic valve will outgrow it and need repeat surgeries just to upsize the replacement. The Ross procedure avoids much of that burden while also sparing young patients from the risks of long-term anticoagulation therapy.
Advantages Over Mechanical and Tissue Valves
The standard alternatives for aortic valve replacement are mechanical valves (made from carbon and metal) and bioprosthetic valves (made from animal tissue). Each comes with significant trade-offs. Mechanical valves are extremely durable but require daily blood-thinning medication for life, carrying a constant risk of serious bleeding. Bioprosthetic valves don’t need blood thinners but tend to wear out within 10 to 15 years, often requiring a second surgery.
The Ross procedure sidesteps both problems. The transplanted valve is your own living tissue. Its leaflets retain their natural flexibility, responsiveness, and ability to repair themselves at the cellular level. This translates to superior blood flow dynamics, lower rates of infection, and a quality of life that more closely matches having a healthy heart. Compared with mechanical valves, the Ross procedure is also associated with lower rates of permanent pacemaker implantation and bleeding complications.
Long-Term Survival and Durability
Long-term data on the Ross procedure is encouraging, particularly for survival. In a large study tracking adults over two decades, survival rates were 97.8% at one year, 94.2% at 10 years, and 81.3% at 20 years. These figures compare favorably to both mechanical and bioprosthetic alternatives in younger patients.
The transplanted pulmonary valve in the aortic position (the autograft) does not last forever in every patient, however. The cumulative rate of needing any reoperation on the autograft or the donor valve was 16% at 10 years, 28% at 15 years, and 45% at 20 years. Most reinterventions involved the autograft rather than the donor valve. One recognized cause is gradual dilation: the pulmonary valve root, now exposed to the higher pressures of the left side of the heart, can slowly stretch over time. In some patients, this leads to a leaky valve that eventually needs repair or replacement.
The donor valve on the right side typically lasts 15 to 20 years before it needs replacing. Because that side of the heart operates at lower pressure, replacing the donor valve is a less complex procedure, and in some cases it can be done using a catheter-based approach rather than repeat open-heart surgery.
Risks Specific to the Ross Procedure
Beyond the general risks of any open-heart surgery (bleeding, infection, reactions to anesthesia), the Ross procedure carries unique concerns. The most significant is autograft dilation, where the transplanted valve gradually widens under aortic pressure. Research has shown that the diameter of the valve root can increase measurably over time, and the surgical technique used affects this risk. Replacing the entire aortic root with the pulmonary root carries a higher dilation risk than techniques that reinforce the transplanted valve within the existing aortic wall.
The operation also converts a single-valve problem into a two-valve situation. If the transplanted pulmonary valve fails in the aortic position, or if the donor valve on the right side wears out, you may need additional surgery on one or both. This is the central trade-off of the Ross procedure: exceptional valve performance and quality of life in exchange for the possibility of future reintervention.
The surgery itself is also more technically demanding than standard valve replacement, which means outcomes depend heavily on the experience of the surgical team. It takes longer on the heart-lung bypass machine and requires precise handling of the coronary arteries. Centers that perform the Ross procedure regularly tend to report better results.
Recovery After Surgery
Recovery follows the general timeline of open-heart surgery. Most patients spend one to two days in the ICU after the operation, followed by several more days on a regular hospital floor. Total hospital stays typically range from five to seven days. You can expect restrictions on lifting and driving for several weeks while the breastbone heals, with a gradual return to normal activity over about two to three months. Cardiac rehabilitation, which involves monitored exercise sessions, is a standard part of recovery and helps rebuild stamina safely.
One of the meaningful quality-of-life benefits becomes apparent in the months after surgery. Unlike patients with mechanical valves, Ross procedure patients do not need to take warfarin or other anticoagulants. This eliminates the need for regular blood testing, dietary restrictions related to blood thinners, and the ongoing bleeding risk that comes with anticoagulation therapy. For younger, active patients especially, this freedom is a major practical advantage.